Breaking News

Financial Report: Novartis 3Q

October 25, 2012

Diovan expiry and currency impact results

Novartis

3Q Revenues: $13.8 billion (-7%)

3Q Earnings: $3.3 billion (-8%)

YTD Revenues: $41.8 billion (-4%)

YTD Earnings: $9.7 billion (-7%)

Comments: Pharmaceutical sales were $7.8 billion in the quarter (-5%), in part due to the U.S. patent expiration of Diovan. Alcon net sales were $2.5 billion (-1%). Sandoz sales declined 13% to $2.0 billion. Vaccines and Diagnostics sales were down 11% to $582 million, driven by lower flu sales and shipment delays from one of the company’s manufacturing sites. Consumer Health, which includes OTC and Animal Health, declined 22% to $938 million, impacted by the continuing absence of shipments from the Lincoln, NE manufacturing site. Currency had a negative impact of 5% in the quarter and 3% YTD.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks